Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHNP-2401
- Development stage
- Preclinical
- Lead developer
- Daehan Nupharm
- Modality
- Small Molecules
01
Overview
DHNP-2401 is a small molecule therapeutic candidate being developed by the South Korean pharmaceutical company Daehan Nupharm for the treatment of obesity. As of current pipeline reports, the drug is in the formulation research stage (제제연구), which involves optimizing the drug's delivery system and physical properties prior to clinical testing. While specific details regarding its biological target and mechanism of action have not been publicly disclosed, it is a key asset in Daehan Nupharm's metabolic disease portfolio, aimed at providing new options for weight management.
Beyond the preview
Go deeper on DHNP-2401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHNP-2401.